Should Pharmacists Stock CBD?
"Pharmacists should do their due diligence and stock products that come from a reputable source."
Writing in Pharmacy Business Magazine, LXR Managing Director, Bill Griffin, outlines the due diligence Pharmacies should take as they consider which CBD products to stock. The article also discusses more context around the CBD market in the UK.
Although the article was published in September 2019 it is still very relevant today and is reinforced by recent guidance from the FSA.
The cornerstone of any background check of a CBD brand is to verify that they implement a rigorous third party testing regime for every batch they produce. This is called the Certificate of Analysis (CoA).
Read about LXR lab reports here.